| 1. |
- Laudanski, P, et al.
(author)
-
Decreased serum level of macrophage inflammatory chemokine-3 beta/CCL19 in preterm labor and delivery
- 2006
-
In: European Journal of Obstetrics, Gynecology, and Reproductive Biology. - : Elsevier BV. - 0301-2115. ; 124:1, s. 23-26
-
Journal article (peer-reviewed)abstract
- Objective: Chemokines are small soluble molecules which mediate leukocyte migration and may be involved in the pathophysiology of preterm labor. We aimed to determine if serum concentrations of selected chemokines are changed in preterm labor and delivery. Study design: A novel array-based enzyme-linked immunosorbent assay was used to quantitate serum levels of nine chemokines from a single sample: MDC/CCL22, TARC/CCL17, ITAC/CXCL11, 1-309/CCL1, IP-10/CXCL10, MIP-1 alpha/CCL3, -1 beta/CCL4, -3 alpha/CCL20 and -3 beta/CCL19. Women in preterm labor who delivered (n = 17), women at preterm pregnancy not in labor (n = 13) and women in labor at term (n = 8) participated. Results: In the preterm delivery group of patients, the MIP-3 beta/CCL19 concentration was in mean (+/- S.D.) 70.4 +/- 31.7 pg/mL, which was significantly lower than that in preterm gravidas not in labor of 123 +/- 34 pg/mL (p < 0.001) and those in labor at term of 118 +/- 25.6 pg/mL (p < 0.01). The other measured chemokines did not differ significantly. Conclusions: Of a small number of examined chemokines, we were able to show that one of them, MIP-3 beta/CCL19 was significantly lower in women with preterm labor and delivery. Whether or not this chemokine has a potential as biochemical marker of preterm delivery remains to be determined. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
|
|
| 2. |
- Pierzynski, P, et al.
(author)
-
Inhibitory effect of barusiban and atosiban on oxytocin-induced contractions of myometrium from preterm and term pregnant women
- 2004
-
In: Journal of the Society for Gynecologic Investigation. - : Springer Science and Business Media LLC. - 1071-5576. ; 11:6, s. 384-387
-
Journal article (peer-reviewed)abstract
- BACKGROUND: A synthetic oxytocin analogue, barusiban, was shown to potently inhibit oxytocin-induced activity of myometrium from term pregnant women. The responsiveness to vasopressin was not influenced by the compound. OBJECTIVE: To test the effect of barusiban and a reference compound, atosiban, on oxytocin-induced activity of myometrium from women at preterm pregnancy in comparison to myometrium from women at term. METHODS: Fifteen preterm (30-36 gestational weeks) and 12 term pregnant women (38-41 weeks) who underwent cesarean delivery donated myometrial tissue for the study. Concentration-response curves following oxytocin, administration to isolated myometrial strips were recorded in control experiments, in the presence of barusiban at concentrations of 2.5, 25, and 250 nM, and of atosiban at concentrations of 25, 250, and 750 nM. Effective concentration 50% (EC50) and pA(2) values were calculated. RESULTS: Both antagonists in higher concentrations increased the EC50 values to oxytocin. The median pA(2) value for preterm myometrium with barusiban was 9.76 and with atosiban 7.86. For term myometrium the corresponding pA(2), results were 9.89 and 7.8 1, respectively. None of these pA(2) values differed to any statistically significant degree. CONCLUSION: The selective oxytocin antagonist, barusiban, concentration-dependently inhibits oxytocin-induced myometrial contractions of both preterm and term myometrium at least as potently as atosiban. It remains to be determined if the selectivity of barusiban for the oxytocin receptor confers an advantage over atosiban as a tocolytic in preterm labor. Copyright (C) 2004 by the Society for Gynecologic Investigation.
|
|
| 3. |
|
|
